Synopsis of recent research by authors named "Jeremy A Ryan"
Jeremy A. Ryan's research primarily focuses on understanding the mechanisms of acquired drug resistance in acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL) through innovative methodologies such as patient-derived xenografts and CRISPR screening.
Recent findings emphasize that low apoptotic priming and specific pathway activations (e.g., RAS/MAPK) play crucial roles in mediating resistance to targeted therapies like venetoclax and other BH3 mimetics in AML.
Ryan's work also highlights the development of new therapeutic strategies targeting vulnerabilities identified through genetic screening and profiling, aiming to improve treatment outcomes for patients with these malignancies.